Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Entry and Attachment Inhibitors

Ibalizumab-uiyk (Trogarzo, IBA)

Last Updated: December 7, 2018; Last Reviewed: December 7, 2018

Excerpt from Table 10a
Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendations Use in Pregnancy
Ibalizumab-uiyk
(IBA)
Trogarzo
IBA (Trogarzo):
  • Solution for IV infusion is available in single-dose vials
Standard Adult Dose:
  • IBA 2000-mg loading dose, followed by IBA 800-mg maintenance doses administered every 2 weeks
Dosing in Pregnancy:
  • Insufficient data are available to make dosing recommendation.
PK in Pregnancy:
  • No PK studies have been reported in human pregnancy.
No data are available, but placental transfer of IBA, a monoclonal antibody, is possible.

Insufficient data are available to assess for teratogenicity in humans.
a Individual ARV drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines, Appendix B, Table 8).

Key to Acronyms: ARV = antiretroviral; IBA = ibalizumab; IV = intravenous; PK = pharmacokinetic

Download Guidelines